[en] Metformin is unanimously considered as the first-line glucose-lowering agent in type 2 diabetes. Theoretically, however, it cannot be prescribed in a large proportion of patients because of the presence of numerous contraindications corresponding to situations that may increase the risk of lactic acidosis. Recent data suggest that type 2 diabetes patients who are considered as being "at risk" because of the presence of cardiac disease still take benefit from metformin therapy, with a reduction of morbidity and mortality compared with other glucose-lowering agents. The present review analyzes the benefit-risk balance of metformin therapy in special populations, namely patients with stable coronary artery disease, acute coronary syndrome or myocardial infarction, or congestive heart failure.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycaemia in type 2 diabetes: A patientcentered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012;55:1577-96.
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
El Messaoudi S, Rongen GA, Riksen NP. Metformin therapy in diabetes: The role of cardioprotection. Curr Atheroscler Rep 2013;15:314.
Anfossi G, Russo I, Bonomo K, et al. The cardiovascular effects of metformin: Further reasons to consider an old drug as a cornerstone in the therapy of type 2 diabetes mellitus. Curr Vasc Pharmacol 2010;8: 327-37.
Lalau JD. Lactic acidosis induced by metformin: Incidence, management and prevention. Drug Saf 2010;33: 727-40.
Scheen AJ. Metformin and lactic acidosis. Acta Clin Belg 2011;66:329-31.
Salpeter SR, Greyber E, Pasternak GA, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2010;CD002967.
Scheen AJ, Paquot N. Metformin revisited: A critical review of the benefit/risk balance in at risk; patients with type 2 diabetes. Diabetes Metab 2013; 39:177-90.
Lipska KJ, Bailey CJ, Inzucchi SE. Use of metformin in the setting of mild-to-moderate renal insufficiency. Diabetes Care 2011;34:1431-7.
Scheen AJ. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease. Expert Opin Drug Metab Toxicol 2013;9:529- 50.
Holman RR, Paul SK, Bethel MA, et al. 10-year follow- up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89.
Monami M, Genovese S, Mannucci E. Cardiovascular safety of sulfonylureas: A meta-analysis of randomized clinical trials. Diabetes Obes Metab 2013; epub ahead of print.
Boussageon R, Supper I, Bejan-Angoulvant T, et al. Reappraisal of metformin efficacy in the treatment of type 2 diabetes: A meta-analysis of randomised controlled trials. PLoS Med 2012;9:e1001204.
Tzoulaki I, Molokhia M, Curcin V, et al. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: Retrospective cohort study using UK general practice research database. BMJ 2009;339:b4731.
Roumie CL, Hung AM, Greevy RA, et al. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: A cohort study. Ann Intern Med 2012;157: 601-10.
Fisman EZ, Tenenbaum A, Benderly M, et al. Antihyperglycemic treatment in diabetics with coronary disease: Increased metformin-associated mortality over a 5-year follow-up. Cardiology 1999;91:195-202. (Pubitemid 29454258)
Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: A nationwide study. Eur Heart J 2011;32:1900-8.
Pantalone KM, Kattan MW, Yu C, et al. Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: A retrospective analysis. Diabetes Obes Metab 2012;14:803-9.
Hong J, Zhang Y, Lai S, et al. Effects of metformin versus glipizide on cardiovascular outcomes in patients with type 2 diabetes and coronary artery disease. Diabetes Care 2013;36:1304-11.
Roussel R, Travert F, Pasquet B, et al. Metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med 2010;170:1892-9.
Inzucchi SE, Masoudi FA, Wang Y, et al. Insulinsensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: Insights from the National Heart Care Project. Diabetes Care 2005;28:1680-9. (Pubitemid 40923078)
Horsdal HT, Johnsen SP, Sondergaard F, et al. Type of preadmission glucose-lowering treatment and prognosis among patients hospitalised with myocardial infarction: A nationwide follow-up study. Diabetologia 2008;51:567-74.
Jorgensen CH, Gislason GH, Andersson C, et al. Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention - a retrospective nationwide cohort study. Cardiovasc Diabetol 2010;9:54.
Jorgensen CH, Gislason GH, Bretler D, et al. Glyburide increases risk in patients with diabetes mellitus after emergent percutaneous intervention for myocardial infarction - a nationwide study. Int J Cardiol 2011; 152:327-31.
Mellbin LG, Malmberg K, Norhammar A, et al. Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: Experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study. Diabetologia 2011;54:1308-17.
Zhao JL, Fan CM, Yang YJ, et al. Chronic pretreatment of metformin is associated with the reduction of the no-reflow phenomenon in patients with diabetes mellitus after primary angioplasty for acute myocardial infarction. Cardiovasc Ther 2013;31:60-4.
Kao J, Tobis J, McClelland RL, et al. Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. Am J Cardiol 2004;93:1347-50, A5.
El Messaoudi S, Rongen GA, de Boer RA, et al. The cardioprotective effects of metformin. Curr Opin Lipidol 2011;22:445-53.
Lexis CP, van der Horst IC, Lipsic E, et al. Metformin in non-diabetic patients presenting with ST elevation myocardial infarction: Rationale and design of the glycometabolic intervention as adjunct to primary percutaneous intervention in ST elevation myocardial infarction (GIPS)-III trial. Cardiovasc Drugs Ther 2012; 26:417-26.
Masoudi FA, Wang Y, Inzucchi SE, et al. Metformin and thiazolidinedione use in Medicare patients with heart failure. JAMA 2003;290:81-5. (Pubitemid 37432869)
Eurich DT, McAlister FA, Blackburn DF, et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: Systematic review. BMJ 2007;335:497.
Papanas N, Maltezos E, Mikhailidis DP. Metformin and heart failure: Never say never again. Expert Opin Pharmacother 2012;13:1-8.
Masoudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: An observational study. Circulation 2005;111:583-90. (Pubitemid 40216485)
Eurich DT, Majumdar SR, McAlister FA, et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 2005;28:2345-51. (Pubitemid 41384275)
Andersson C, Olesen JB, Hansen PR, et al. Metformin treatment is associated with a low risk of mortality in diabetic patients with heart failure: A retrospective nationwide cohort study. Diabetologia 2010;53:2546-53.
MacDonald MR, Eurich DT, Majumdar SR, et al. Treatment of type 2 diabetes and outcomes in patients with heart failure: A nested case-control study from the U.K. General Practice Research Database. Diabetes Care 2010;33:1213-8.
Aguilar D, Chan W, Bozkurt B, et al. Metformin use and mortality in ambulatory patients with diabetes and heart failure. Circ Heart Fail 2011;4:53-8.
Eurich DT, Weir DL, Majumdar SR, et al. Comparative safety and effectiveness of metformin in patients with diabetes mellitus and heart failure: Systematic review of observational studies involving 34'000 patients. Circ Heart Fail 2013;6:395-402.
Eurich DT, Tsuyuki RT, Majumdar SR, et al. Metformin treatment in diabetes and heart failure: When academic equipoise meets clinical reality. Trials 2009; 10:12.
Boyd A, Nawarskas J. Metformin use in decompensated heart failure. Cardiol Rev 2008;16:269-72.
Tahrani AA, Varughese GI, Scarpello JH, et al. Metformin, heart failure, and lactic acidosis: Is metformin absolutely contraindicated? BMJ 2007;335:508-12. (Pubitemid 47401613)
Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary. The task force on diabetes and cardiovascular diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28:88- 136. (Pubitemid 46137814)
Beck E, Scheen AJ. Activité anticancéreuse de la metformine: nouvelles perspectives pour une vieille molécule. Rev Med Suisse 2010;6:1601-7.
Beck E, Scheen AJ. Quels bénéfices anti-tumoraux attendre de la metformine? Ann Endocrinol (Paris) 2013;74:137-47.
Kooy A, de Jager J, Lehert P, et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 2009;169:616-25.
Whittington HJ, Hall AR, McLaughlin CP, et al. Chronic metformin associated cardioprotection against infarction: Not just a glucose lowering phenomenon. Cardiovasc Drugs Ther 2013;27:5-16.
Holstein A, Stumvoll M. Contraindications can damage your health - is metformin a case in point? Diabetologia 2005;48:2454-9. (Pubitemid 41738207)